Premium
Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed‐ratio combination: a post hoc analysis of the LixiLan‐O and LixiLan‐L trials
Author(s) -
Davidson J. A.,
Desouza C.,
Fonseca V.,
Frias J. P.,
Van Gaal L.,
Giorgino F.,
Chao J.,
Dex T. A.,
Roberts M.,
Saremi A.,
Leiter L. A.
Publication year - 2020
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.14094
Subject(s) - medicine , lixisenatide , insulin glargine , postprandial , post hoc analysis , type 2 diabetes , diabetes mellitus , plasma glucose , insulin , endocrinology , basal insulin
Aims Both fasting ( FPG ) and postprandial plasma glucose ( PPG ) contribute to HbA 1c levels. We investigated the relationship between achievement of American Diabetes Association ( ADA ) and American Association of Clinical Endocrinologists ( AACE ) recommended FPG and/or PPG targets and glycaemic efficacy outcomes in two trials. Methods In this post hoc analysis, data from participants with Type 2 diabetes in the phase 3 LixiLan‐O ( NCT 02058147) and LixiLan‐L ( NCT 02058160) trials were evaluated to compare the relationship between achievement of society‐recommended FPG and/or PPG targets and efficacy (HbA 1c change, HbA 1c goal attainment, weight change) and safety outcomes in the treatment groups. Results Across treatment arms, iG larLixi achieved the highest proportion of participants meeting both ADA ‐ and AACE ‐recommended FPG and PPG targets at study end in both trials. A higher proportion of participants in the iG larLixi (fixed‐ratio combination of insulin glargine and lixisenatide) vs. insulin glargine alone or lixisenatide alone treatment arms achieved HbA 1c goals ( P < 0.001 for overall comparisons), irrespective of ADA ‐ or AACE ‐defined targets. Hypoglycaemia rates [any, documented symptomatic (plasma glucose ≤ 3.9 mmol/l), and clinically important (plasma glucose < 3.0 mmol/l)] were low across all groups. Participants treated with iG larLixi tended to show weight loss or less weight gain compared with participants receiving insulin glargine alone. No differences were observed in average daily basal insulin dose at week 30 between the two treatment arms or across the different FPG and PPG target groups. Conclusion Insulin glargine and lixisenatide as a fixed‐ratio combination resulted in more participants reaching both FPG and PPG targets, leading to better HbA 1c target attainment.